Phathom Pharmaceuticals Operating Margin vs. Net Income

PHAT Stock  USD 13.61  0.54  3.82%   
Based on Phathom Pharmaceuticals' profitability indicators, Phathom Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in February. Profitability indicators assess Phathom Pharmaceuticals' ability to earn profits and add value for shareholders.

Phathom Pharmaceuticals Operating Profit Margin

(4.75)

Price To Sales Ratio is likely to drop to 10.14 in 2026. Days Sales Outstanding is likely to drop to 280.00 in 2026. At this time, Phathom Pharmaceuticals' Interest Income is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 50.4 M in 2026, despite the fact that Net Loss is likely to grow to (285.8 M). Gross Profit is likely to gain to about 57.1 M in 2026, whereas Pretax Profit Margin is likely to drop (5.72) in 2026.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.650.77
Fairly Down
Very volatile
For Phathom Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Phathom Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Phathom Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Phathom Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Phathom Pharmaceuticals over time as well as its relative position and ranking within its peers.
Check out Your Equity Center.
For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.By analyzing Phathom Pharmaceuticals' earnings estimates, investors can diagnose different trends across Phathom Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Phathom Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Phathom Pharmaceuticals is projected to generate -0.02795 in earnings per share on the 31st of December 2026. Phathom Pharmaceuticals earnings estimates show analyst consensus about projected Phathom Pharmaceuticals EPS (Earning Per Share). It derives the highest and the lowest estimates based on Phathom Pharmaceuticals' historical volatility. Many public companies, such as Phathom Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Phathom Pharmaceuticals' earnings estimates, investors can diagnose different trends across Phathom Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phathom Pharmaceuticals. If investors know Phathom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phathom Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.76)
Revenue Per Share
2.038
Quarterly Revenue Growth
2.027
Return On Assets
(0.43)
Return On Equity
(34.89)
The market value of Phathom Pharmaceuticals is measured differently than its book value, which is the value of Phathom that is recorded on the company's balance sheet. Investors also form their own opinion of Phathom Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phathom Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phathom Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phathom Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phathom Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phathom Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phathom Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Phathom Pharmaceuticals Net Income vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Phathom Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Phathom Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Phathom Pharmaceuticals is regarded second in operating margin category among its peers. It is rated below average in net income category among its peers . At this time, Phathom Pharmaceuticals' Operating Profit Margin is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Phathom Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Phathom Net Income vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Phathom Pharmaceuticals

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(0.31) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Phathom Pharmaceuticals

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(334.33 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Phathom Net Income Comparison

Phathom Pharmaceuticals is currently under evaluation in net income category among its peers.

Phathom Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Phathom Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Phathom Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Phathom Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Phathom Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Interest Income-51.2 M-48.6 M
Interest Income17.4 M18.3 M
Operating Income-249.7 M-237.2 M
Net Loss-300.9 M-285.8 M
Income Before Tax-300.9 M-285.8 M
Total Other Income Expense Net-65.4 M-68.7 M
Net Loss-178 M-186.8 M
Net Loss-300.9 M-285.8 M
Income Tax Expense48 M50.4 M
Non Operating Income Net Other-1.8 M-1.7 M
Change To Netincome38.7 M47.3 M
Net Loss(6.09)(6.39)
Income Quality 0.72  0.54 
Net Income Per E B T 0.74  0.66 

Phathom Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Phathom Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Phathom Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Phathom Pharmaceuticals' important profitability drivers and their relationship over time.

Phathom Pharmaceuticals Earnings per Share Projection vs Actual

Use Phathom Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phathom Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phathom Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Phathom Pharmaceuticals Pair Trading

Phathom Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Phathom Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phathom Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phathom Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phathom Pharmaceuticals to buy it.
The correlation of Phathom Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phathom Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phathom Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phathom Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Phathom Pharmaceuticals position

In addition to having Phathom Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Long Short Funds Thematic Idea Now

Long Short Funds
Long Short Funds Theme
Funds or Etfs that are designed to hedge away market risk by investing in combination of bonds, stocks, derivative instruments as well as short positions to maximize returns irrespective of market conditions. The Long Short Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long Short Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.